Therapeutic Programs

Aileron is developing a broad and growing pipeline of Stapled Peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases, and inflammation.

Aileron is advancing our lead oncology program − a highly potent, full re-activator of the p53 pathway − with the potential to deliver superior efficacy and safety in a broad spectrum of solid and hematological malignancies. The development candidate entered clinical trials in 2014.